rFVIIIFc (efraloctocog alfa, Eloctate®) is an extended half-life (EHL) factor VIII licensed for
use in patients with hemophilia A for prophylaxis and treatment of bleeding and surgical …

Introduction Nuwiq®[human cell line‐derived recombinant factor VIII (human‐cl rhFVIII)] is a
new generation rFVIII protein, without chemical modification or fusion to any other protein …

Background Prophylactic factor replacement, which prevents hemarthroses and thereby
reduces the musculoskeletal disease burden in children with hemophilia A, requires …

Introduction Nuwiq®(Human‐cl rh FVIII) is a new‐generation recombinant factor VIII (rFVIII)
protein, without chemical modification or fusion to any other protein, produced in a human …

BACKGROUND: Recombinant factor VIII (rFVIII) products have been developed with
improved pharmacokinetics, offering some patients the potential to extend dosing intervals …

Essentials• No randomized trials have compared long‐acting factor VIII (FVIII) with currently
used products.• A comparison was undertaken using a decision model to predict FVIII use …

Introduction Haemophilia A is a rare bleeding disorder caused by coagulation factor VIII
(FVIII) deficiency. This is treated with factor VIII, conventionally using products with a half-life …

Abstract Treatment data for >= 6 months before switching to rFVIIIFc were available for
89.2% of patients being treated prophylactically with rFVIIIFc (I ni= 83/93; patients with …

Background Recurrent joint bleeds are a major cause of morbidity in severe hemophilia.
Prophylaxis with efmoroctocog alfa (a recombinant factor VIII Fc fusion protein,[rFVIIIFc]) has …

We thank Horneff et al for their comment1 on our earlier article. 2 As detailed in the
introduction section, we reported on the design and results of pivotal and extension studies …